Results 191 to 200 of about 16,696 (258)

Artemisinins in autoimmune diseases: effects and mechanisms in systemic lupus erythematosus and rheumatoid arthritis

British Journal of Pharmacology, Volume 182, Issue 15, Page 3411-3427, August 2025.
Abstract Autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) result from immune self‐tolerance loss, causing tissue damage. Standard treatments targeting late‐stage inflammation often have serious side effects. Artemisinin, known for its antimalarial properties, shows potential immunomodulatory effects.
Fanchao Zhou, Guoming Li, Ruixiang Tan, Guodong Wu, Changsheng Deng   +4 more
wiley   +1 more source

Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta-analysis of randomized trials. [PDF]

Intensive Care Med Exp, 2020
Tarazan N, Alshehri M, Sharif S, Al Duhailib Z, Møller MH, Belley-Cote E, Alshahrani M, Centofanti J, McIntyre L, Baw B, Meade M, Alhazzani W, GUIDE Group.   +12 more
europepmc   +1 more source

Neuromuscular blocking agents for patients with acute respiratory distress syndrome [PDF]

, 2014
Guang Ying Zhuo, Qing‐Yu He, Li J Yang, Guan J Liu, Jonathan N Rajan   +4 more
openalex   +1 more source

Beyond the Surface: Investigating the Potential Mechanisms of Non‐Motor Symptoms in Myasthenia Gravis

European Journal of Neurology, Volume 32, Issue 8, August 2025.
We review the non‐motor symptoms of MG and their potential pathogenesis, hoping to contribute to personalized diagnosis and treatment. ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction (NMJ), driven by T cells, mediated by B cells, and dependent on autoantibodies.
Benqiao Wang, Dan Liu, Yingying Yang, Ruixia Zhu   +3 more
wiley   +1 more source

Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study. [PDF]

Crit Care, 2020
Courcelle R, Gaudry S, Serck N, Blonz G, Lascarrou JB, Grimaldi D, on behalf the COVADIS study group.   +6 more
europepmc   +1 more source

Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents [PDF]

, 2015
Friederike Haerter, Jeroen Cedric Peter Simons, Urs Foerster, Ingrid Moreno‐Duarte, Daniel Diaz‐Gil, Shweta Ganapati, Katharina Eikermann‐Haerter, Cenk Ayata, Ben Zhang, Manfred Blobner, Lyle Isaacs, Matthias Eikermann   +11 more
openalex   +1 more source

Neural Stem Cell‐Derived Extracellular Vesicles for Advanced Neural Repair

Journal of Neurochemistry, Volume 169, Issue 8, August 2025.
Neurodegenerative and neuroinflammatory diseases, such as Alzheimer's and multiple sclerosis (MS), are characterized by inflammation, nerve cell damage, and a limited capacity for natural repair, which worsens with aging. While neural stem cells (NSCs) show promise for brain repair, their clinical use is limited by safety and delivery challenges.
Eduardo H. Moretti, Ally L. Y. Lin, Luca Peruzzotti‐Jametti, Stefano Pluchino, Sabah Mozafari   +4 more
wiley   +1 more source

Antibiotic-induced immediate type hypersensitivity is a risk factor for positive allergy skin tests for neuromuscular blocking agents [PDF]

, 2015
Natalia Hagău, Nadia Gherman, Mihaela Cociş, Cristina Petrișor   +3 more
openalex   +1 more source

Efficacy of Botulinum Toxin A for the Management of Melasma: A Split‐Face, Randomized Control Study

Journal of Cosmetic Dermatology, Volume 24, Issue 8, August 2025.
ABSTRACT Background Melasma management remains challenging due to its multifactorial nature pathogenesis and recurrent nature. Previous studies showed positive effects of botulinum toxin A (BoNT‐A) for treating and preventing ultraviolet‐induced hyperpigmentation.
Sasipim Chaijaras, Suphagan Boonpethkaew, Sonphet Chirasuthat, Nawara Sakpuwadol, Tanat Yongpisarn, Pimsiri Anansiripun, Vasanop Vachiramon   +6 more
wiley   +1 more source